Exact Mass: 522.1795914
Exact Mass Matches: 522.1795914
Found 64 metabolites which its exact mass value is equals to given mass value 522.1795914,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Ticagrelor
Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
Prednisolone phthalate
5-Hydroxy-7-methoxy-3,4-diacetoxy-6-(6,6-dimethyl-2-oxo-cyclohexylmethyl)flavone
10-O-benzoyl-10-O-deacetyl-11-demethoxy-11-ethoxydaphylloside|ethyl(1S,4aS,5S,7aS)-7-[(benzoyloxy)methyl]-1-(beta-D-glucopyranosyloxy)-1,4a,5,7a,-tetrahydro-5-hydroxycyclopenta[c]pyran-4-carboxylate
4-cumaryl alcohol 4-O-beta-D-glucopyranoside peracetate|[4-(3-Acetoxy-trans-propenyl)-phenyl]-(tetra-O-acetyl-beta-D-glucopyranosid)|[4-(3-acetoxy-trans-propenyl)-phenyl]-(tetra-O-acetyl-beta-D-glucopyranoside)
benzyl 2-O-beta-D-apiofuranosyl-(1?2)-beta-D-glucopyranosylbenzoate
1beta-(3-furanoyloxy)-9alpha-benzoyloxy-8beta-acetoxy-2-oxo-3-enedihydro-beta-agarofuran
10-O-Trans-p-methoxycinnamoylcatalpol
Ticagrelor
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent > C190801 - P2Y12 Inhibitor D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
C25H30O12_(5E)-5-[2-(beta-D-Glucopyranosyloxy)ethylidene]-4-{[(2E)-3-(4-hydroxy-3-methoxyphenyl)-2-propenoyl]oxy}-2-methyl-1-cyclopentene-1-carboxylic acid
C25H30O12_(1S,4aS,6S,7R,7aS)-1-(beta-D-Glucopyranosyloxy)-6-{[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]oxy}-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid
C25H30O12_Cyclopenta[c]pyran-4-carboxylic acid, 1,4a,5,6,7,7a-hexahydro-7-hydroxy-1-[[2-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-beta-D-glucopyranosyl]oxy]-7-methyl-, (1S,4aS,7R,7aS)
Asp Asp His His
Asp His Asp His
Asp His His Asp
His Asp Asp His
His Asp His Asp
His His Asp Asp
2-methyl-6-phenyl-4-(2-phenylethynyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-ethyl ester O5-[(4-nitrophenyl)methyl] ester
MRS1334 is a potent and selective human adenosine A3 receptor antagonist with Kis of 2.69 nM, >100 nM, >100 nM for hA3, rA1, rA2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment[1][2]. MRS1334 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
23,26-Dihydroxy-23-(2-hydroxyacetyl)-1,24-dimethyl-3,12-dioxahexacyclo[14.11.0.02,13.05,10.019,27.020,24]heptacosa-2(13),5,7,9,15-pentaene-4,11,14-trione
3,15-Di-O-acetylbruceolide
A quassinoid that is the 3,15-di-O-acetyl derivative of bruceolide. It has been isolated from Brucea javanica and Brucea sumatrana.
4-methyl-N-[5-[2-[2-[[1-[(4-methylphenyl)methyl]indol-3-yl]methylidene]hydrazinyl]-2-oxidanylidene-ethyl]-1,3,4-thiadiazol-2-yl]benzamide
5-(beta-D-glucopyranosyloxy)-1H-naphtho[2,3-c]pyran-10-yl beta-D-quinovopyranoside
[(1R)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-2-[(4-chlorophenyl)methyl]-7-methoxy-1-(2-thiazolylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(1R,2S,3R,5S)-3-[7-[[(1R,2R)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
clarinoside
A naphthopyran that is 1H-naphtho[2,3-c]pyran-5,10-diol in which the hydroxy group at position 5 (furthest from the pyran oxygen) has been converted to the corresponding beta-D-glucoside, while that at position 10 has been converted to the corresponding 6-deoxy-beta-D-glucopyranoside (beta-D-quinovoside). It was isolated from the flowered aerial parts of the annual plant Mitracarpus scaber.